rheumatologists

Different Prostacyclin Analogs Can Help Treat Pediatric PAH

Researchers provided a comprehensive overview of the advantages and drawbacks of prostacyclin and its analogs for the treatment of pulmonary arterial hypertension (PAH) in pediatric patients, as published in European Review for Medical and Pharmacological Sciences. “Epoprostenol can be effective against severe pulmonary hypertension,” the authors said. Iloprost, on the other hand, can treat severe…

SIRT3 Enzyme Could Help Develop New PAH Therapies

The sirtuin 3 (SIRT3) enzyme may prevent the development of cardiovascular diseases such as pulmonary arterial hypertension (PAH) by protecting the mitochondria, according to a new review published in Free Radical Biology and Medicine. Therefore, sirtuin 3 agonists may serve as potential treatments for cardiovascular diseases, the authors said. SIRT3 is a deacetylase that regulates…

Newly Identified ICU Characteristics May Help Reduce Mortality in CAD

Researchers reported the characteristics and outcomes of adult patients with severe autoimmune hemolytic anemia (AIHA) admitted to the intensive care unit (ICU), as presented at the 63rd American Society for Hematology Annual Meeting & Exposition. AIHA is known to carry a poor prognosis and studies have indicated that the overall mortality rate is between 8% to…

Breathing Reserve at Peak Exercise May Not Provide IPAH Prognostic Value

Researchers discovered that patients’ breathing reserve at peak exercise was not associated with disease outcomes in idiopathic pulmonary arterial hypertension (IPAH), as published in the International Journal of Cardiology Congenital Heart Disease. In contrast, they found an association between breathing reserve >30% at peak exercise and improved survival rates in patients with Eisenmenger syndrome (EIS).…

Study Suggests COVID-19 Could Exacerbate CAD

Researchers presented the case of an 83-year old woman with secondary cold agglutinin disease (CAD) whose disease worsened due to a COVID-19 infection, as published in Cureus. “Association between COVID-19 and [cold agglutinin syndrome] is a recent and novel finding,” Yash V. Bhagat and the coauthors of the study wrote. “The lack of established evidence-based…

Researchers Emphasize Clinical and Immunohematology Testing for CAD

A patient was diagnosed with cold agglutinin syndrome (CAS) after the discovery of cold-antibody autoimmune hemolytic anemia (cAIHA) and splenic marginal zone lymphoma (MZL), as published in Hematology, Transfusion and Cell Therapy. CAS was recently described as a separate but similar entity to cold agglutinin disease (CAD). “In [CAD], patients may have a B-cell clonal…

Novel Therapeutics Proposed Could Improve Clinical Outcomes in CAD

Migdady and colleagues conducted a literature review on immune-mediated anemia occurring after hematopoietic stem cell transplantation (HCT) and presented their findings in a study published in Blood Advances. “Auto- or alloimmunity against the RBC [red blood cell] are an important etiology of immune-mediated anemia in blood group mismatched HCT,” they wrote. “The source of auto-…

Targeting MMP-10 Could Be Therapeutic in PAH

The matrix metalloproteinase-10 (MMP-10) enzyme that’s produced by infiltrating macrophages contributes to vascular remodeling in pulmonary arterial hypertension (PAH), a new study published in the International Journal of Biological Sciences found. This finding suggests that circulating MMP-10 could be used as a potential therapy for PAH, Pei-Ling Chi and the coauthors of the study said.…

Inhibition of TRCP6 Shows Therapeutic Potential in PAH

Inhibition of transient receptor potential channel 6 (TRPC6) may be a novel therapeutic approach for treating pulmonary arterial hypertension (PAH), according to a new study published in the American Journal of Physiology – Lung Cellular and Molecular Physiology. The results showed that the administration of BI-749327, a selective blocker of TRCP6, resulted in roughly 50%…

Next post in PAH News Briefs